Authors: Piera Neill, The University of Auckland; Honorary Associate Professor Paul Jarrett, Dermatologist, Middlemore Hospital and Department of Medicine, The University of Auckland, New Zealand (2022) Previous contributors: Hon A/Prof Amanda Oakley, Dermatologist (2014); Vanessa Ngan (2003)
Generalisedpustular psoriasis (GPP) is a rare, severe form of pustular psoriasis. It is characterised by recurrent flares of widespread sterile pustules with erythematous, painful skin. GPP can be associated with systemicinflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement.
It is also known as von Zumbusch psoriasis.
Generalised pustular psoriasis
Generalised pustular psoriasis
Generalised pustular psoriasis
Pustular psoriasis on a limb in skin of colour
Generalised pustular psoriasis
Superficial pustules in generalised pustular psoriasis
GPP can appear in any age group, although is most common in adults between 40–50 years old and is unusual in children. The age of onset is often earlier in patients with a family history of psoriasis, or with a homozygousinterleukin 36 (IL-36) receptor antagonist (IL36RN) genemutation.
Females are generally more likely to be affected, although, for paediatric onset between 3–16 years of age, a male predominance has been reported.
GPP can also affect pregnant women, which is termed impetigo herpetiformis, and is associated with increased maternal and fetal morbidity.
Although GPP is distinct from plaque psoriasis, the two conditions are strongly associated with one another, making concurrent or previous plaque psoriasis a significant risk factor for developing GPP.
What causes generalised pustular psoriasis?
The exact pathogenic mechanisms are not fully established. However, GPP is associated with a combination of genetic and environmental risk factors.
Genetic predispositions
Several genetic mutations are associated with GPP, including homozygous and heterozygous mutations in genes involved in the regulation of immune and inflammatory pathways, such as:
IL36RN (interleukin 36 receptor antagonist) — homozygous or compound heterozygous mutations are associated with GPP not accompanied by plaque psoriasis
CARD14 (caspase recruitment domain-containing protein 14) — significant risk for GPP with plaque psoriasis
AP1S3 (adaptor-related protein complex 1 subunit sigma 3)
MPO (myeloperoxidase)
SERPINA3 (Serpin peptidase inhibitor clade A member 3).
Genetic screening for GPP may potentially be available in future.
Environmental risk factors
Use of (or tapering/stopping) various medications may be associated with GPP, such as:
What are the clinical features of generalised pustular psoriasis?
Cutaneous features
Inflammation (redness, swelling, tenderness, itch) develops initially, usually in areas of large skinfolds.
Within 2–3 hours, 2–3mm sterile non-follicular pustules appear, which then converge to form ‘lakes’ of pus. The trunk and limbs are most commonly affected.
Over the following days to weeks, pustules dry out and usually resolve with residual erythema and desquamation, or may evolve into erythrodermic psoriasis.
How do clinical features vary in differing types of skin?
The varying clinical presentation of GPP between differing skin types is not well documented, mainly due to the rarity of the disease. Erythema can be under-recognised in skin of colour, and therefore the severity of inflammation can be underestimated.
What are the complications of generalised pustular psoriasis?
Complications of acute skin failure include:
Bacteraemia/septicaemia
Fluid loss with hypovolaemia
Impaired thermoregulatory control
Metabolic disturbance.
Other potential complications of GPP:
Peripheralneuropathy
Enteropathy
Malabsorption of nutrients and medications
Disturbed protein and electrolyte balance
Renal impairment
Acute respiratory distress syndrome
Pancreatitis
Neutrophilic cholangitis leading to cholestasis
Cardiac failure.
Such complications can be fatal. Death can result from cardiorespiratory failure during the acute eruptive phase of generalised pustular psoriasis, so it is essential to treat it as early as possible. Older patients are at particularly high risk.
Maternal GPP can result in foetal abnormalities, preterm birth, placental insufficiency, and neonatal death.
How is generalised pustular psoriasis diagnosed?
GPP can be a diagnostic challenge due to its rarity, its heterogeneouscutaneous and extracutaneous symptomatology, its similarity to other conditions such as acute generalised exanthematous pustulosis, and the lack of standardised international diagnostic criteria.
According to the 2018 Japanese guidelines, a definitive diagnosis of GPP can be made in patients with all four of the following features:
Systemic symptoms such as fever and fatigue
Extensive or systemic flushing accompanied by multiple sterile pustules that can coalesce into lakes of pus
Neutrophilic subcorneal pustules, histopathologically characterised by Kogoj’s spongiform pustules
Repeated recurrences of these clinical and histopathological findings.
GPP would be diagnosed if all four of the above features were present and would be suspected in patients with features 2 and 3.
What is the treatment for generalised pustular psoriasis?
GPP is severe, and complications can be life-threatening. It should be treated promptly and usually hospitalisation is needed. Intensive care support may be necessary.
Interleukin 36 (IL-36) antagonists — spesolimab. Imsidolimab is currently under investigation.
What is the outcome of generalised pustular psoriasis?
GPP is an incurable condition, with an unpredictable and variable course.
Although treatment aims to prevent and reduce the frequency and duration of flares, most patients have recurrent disease. The time interval between flares ranges from weeks to years, and the severity of flares is also fluctuant. There may or may not be complete regression of lesions after flares, and symptoms have been reported to persist between flares in ~80% of cases.
Data on mortality rates are limited, but have been reported between 3–7%. Older patients likely have a poorer prognosis than younger patients due to comorbidities and systemic complications.
Fujita H, Gooderham M, Romiti R. Diagnosis of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):31–38. doi:10.1007/s40257-021-00652-1. PubMed
Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol. 2018 Nov;45(11):1235-1270. doi: 10.1111/1346-8138.14523. PubMed
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10): 1645–51. doi:10.1111/jdv.14949. PubMed
Krueger J, Puig L, Thaçi D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51–64. doi:10.1007/s40257-021-00658-9. PubMed
Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37–42. Published 2019 Jun 20. doi:10.2147/PTT.S181808. PubMed
Romiti R, Hirayama ALDS, Arnone M, Magalhães RF. Generalized pustular psoriasis (von Zumbusch). An Bras Dermatol. 2022;97(1):63–74. doi:10.1016/j.abd.2021.05.011. PubMed